Video

Dr. Paz-Ares Discusses the Use of Pemetrexed for NSCLC

Author(s):

Luis Paz-Ares, MD, PhD

Dr. Paz-Ares From Seville University Hospital Discusses the Use of Pemetrexed for NSCLC

Luis Paz-Ares, MD, PhD the chair of oncology at Seville University Hospital in Spain discusses the use of pemetrexed in advanced nonsquamous non—small cell lung cancer.

Related Videos
Benjamin Besse, MD, PhD, director, clinical research, Gustave Roussy Institute; professor, medical oncology, Paris-Saclay University
Fred Saad, CQ, MD, FRCS, FCAHS
Eric Kumar Singhi, MD
Seth Wander, MD, PhD
Lillian L. Siu, MD, FRCPC
Marc Machaalani, MD
Mark Awad, MD, PhD, chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Rasha Cosman, BSc, MBBS, FRACP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Nicholas P. McAndrew, MD, MSCE
Related Content
Kristin A. Higgins, MD, chief clinical officer, City of Hope Cancer Center Atlanta
October 6th 2024

Atezolizumab Plus Chemoradiation Provides No Survival Benefit in LS-SCLC

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

FDA recap thumb
October 4th 2024

OncLive’s September Roundup of Key FDA Approvals in Oncology

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

FDA
October 3rd 2024

FDA Approves Perioperative Nivolumab for Resectable NSCLC

Pietro Bersani, chief executive officer, Kiromic BioPharma
October 1st 2024

Allogeneic T-Cell Therapy Produces Efficacy at 10 Months in Stage IV Metastatic NSCLC